Results 11 to 20 of about 64,314 (239)

Update on the use of etanercept across a spectrum of rheumatoid disorders

open access: yesBiologics: Targets & Therapy, 2008
Bernard CombeService d’Immuno-Rhumatologie, Montpellier, FranceAbstract: Etanercept is a soluble TNF receptor p75 fusion protein which is approved for subcutaneous use (50 mg weekly) in the treatment of patients with active rheumatoid arthritis
Bernard Combe
doaj   +1 more source

Nail Lichen Planus: Successful Treatment with Etanercept [PDF]

open access: yesCase Reports in Dermatology, 2010
Background: Etanercept is a fully human tumor necrosis factor α receptor fusion protein that binds tumor necrosis factor α with greater affinity than natural receptors.
N. Irla   +3 more
doaj   +3 more sources

Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update

open access: yesJournal of Inflammation Research, 2009
Siegfried SegaertDepartment of Dermatology, University Hospital Leuven, BelgiumAbstract: Etanercept, a subcutaneously administered fully human soluble tumor necrosis factor (TNF) receptor, was initially approved for the treatment of psoriasis at a dose ...
Siegfried Segaert
doaj   +1 more source

Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis

open access: yesPatient Preference and Adherence, 2013
José Miguel Senabre-Gallego,1 Carlos Santos-Ramirez,2 Gregorio Santos-Soler,1 Esteban Salas-Heredia,1 Mabel Sánchez-Barrioluengo,3 Xavier Barber,4 José Rosas1 On behalf of the AIRE-MB group 1Rheumatology, Hospital Marina Baixa ...
Senabre-Gallego JM   +6 more
doaj   +1 more source

Etanercept (Enbrel®) alternative storage at ambient temperature

open access: yesClinical Pharmacology: Advances and Applications, 2017
Edel Shannon,1 Joanne Daffy,2 Heather Jones,3 Andrea Paulson,4 Steven M Vicik5 1Global Chemistry, Manufacturing, and Controls Regulatory, 2Contract Operations Quality Assurance, Pfizer Ireland Pharmaceuticals, Clondalkin, Dublin, Ireland; 3Medical ...
Shannon E   +4 more
doaj   +1 more source

SOX30 Facilitates Triple-Negative Breast Cancer Metastasis via TNFR2-NF-κB Signaling and Tumor Microenvironment Remodeling. [PDF]

open access: yesAdv Sci (Weinh)
SOX30 drives triple‐negative breast cancer (TNBC) metastasis through a dual mechanism: direct activation of the TNFR2/NF‐κB signaling cascade and subsequent CCL20‐mediated recruitment of tumor‐associated macrophages (TAMs) into the tumor microenvironment.
Gao P   +10 more
europepmc   +2 more sources

Late Onset Prosthetic Hip Joint Infection in Two Patients of Rheumatoid Arthritis Treated With Etanercept

open access: yesArchives of Rheumatology, 2015
In this article, we report two rheumatoid arthritis (RA) patients who developed rare, late onset infection after total hip arthroplasty (THA) following etanercept therapy. First patient was a 74-year-old female with RA.
Hayashi SHINYA   +6 more
doaj   +3 more sources

Comparison of the inhibitory effect of tocilizumab and etanercept on the progression of joint erosion in rheumatoid arthritis treatment

open access: yesScientific Reports, 2022
We compared the efficacy of tocilizumab and etanercept in inhibiting radiographic progression of joint destruction in rheumatoid arthritis. Overall, 187 patients treated with etanercept or tocilizumab were selected.
Shinya Hayashi   +11 more
doaj   +1 more source

Baseline characteristics and patient reported outcome data of patients prescribed etanercept: web-based and telephone evaluation [PDF]

open access: yes, 2011
<p>Background: The anti-TNF inhibitor, etanercept is administered as a once or twice weekly subcutaneous injection for the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis ...
Alex McConnachie   +11 more
core   +2 more sources

Intra-articular vs. systemic administration of etanercept in antigen-induced arthritis in the temporomandibular point. Part I: histological effects

open access: yesPediatric Rheumatology Online Journal, 2009
Background Temporomandibular joint (TMJ) arthritis in children causes alterations in craniomandibular growth. This abnormal growth may be prevented by an early anti-inflammatory intervention.
Nyengaard Jens R   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy